Aceragen Announces Recommendation Of Data Monitoring Committee In Terra Study
Aceragen, Inc. (NASDAQ:ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its